AIMS: To define the N-terminal pro-brain natriuretic peptide (NTpBNP) normal range, assessing its cardiovascular screening characteristics in general population and higher risk subjects. METHODS AND RESULTS: A total of 2320 subjects (1392 general population and 928 high-risk) > or =45 years old, selected randomly from seven community practices, were invited to undergo clinical assessment and echocardiography and to assess NTpBNP serum levels. Of these, 1205 attended. The NTpBNP normal range was calculated and its cardiovascular screening characteristics were assessed. Age (P<0.0001) and female gender (P<0.0001) independently predicted NTpBNP levels in normal subjects. In the general population, age- and gender-stratified normal NTpBNP levels gave a negative-predictive value (NPV) of 99% in excluding left ventricular systolic dysfunction, atrial fibrillation, and valvular heart disease, and a positive predictive value of 56% in detecting any cardiovascular disease assessed. In high-risk subjects, these values were 98 and 62%, respectively. Ninety-five per cent of subjects with NTpBNP levels over four times the normal had significant cardiovascular disease with the others having renal dysfunction. CONCLUSION: Normal NTpBNP levels should be stratified by age and gender. Normal NTpBNP levels give high NPV in excluding significant cardiovascular disease. Most subjects with raised NTpBNP levels and almost all subjects with NTpBNP levels over four times the normal have significant cardiovascular disease.
AIMS: To define the N-terminal pro-brain natriuretic peptide (NTpBNP) normal range, assessing its cardiovascular screening characteristics in general population and higher risk subjects. METHODS AND RESULTS: A total of 2320 subjects (1392 general population and 928 high-risk) > or =45 years old, selected randomly from seven community practices, were invited to undergo clinical assessment and echocardiography and to assess NTpBNP serum levels. Of these, 1205 attended. The NTpBNP normal range was calculated and its cardiovascular screening characteristics were assessed. Age (P<0.0001) and female gender (P<0.0001) independently predicted NTpBNP levels in normal subjects. In the general population, age- and gender-stratified normal NTpBNP levels gave a negative-predictive value (NPV) of 99% in excluding left ventricular systolic dysfunction, atrial fibrillation, and valvular heart disease, and a positive predictive value of 56% in detecting any cardiovascular disease assessed. In high-risk subjects, these values were 98 and 62%, respectively. Ninety-five per cent of subjects with NTpBNP levels over four times the normal had significant cardiovascular disease with the others having renal dysfunction. CONCLUSION: Normal NTpBNP levels should be stratified by age and gender. Normal NTpBNP levels give high NPV in excluding significant cardiovascular disease. Most subjects with raised NTpBNP levels and almost all subjects with NTpBNP levels over four times the normal have significant cardiovascular disease.
Authors: David L Garbers; Ted D Chrisman; Phi Wiegn; Takeshi Katafuchi; Joseph P Albanesi; Vincent Bielinski; Barbara Barylko; Margaret M Redfield; John C Burnett Journal: Trends Endocrinol Metab Date: 2006-06-30 Impact factor: 12.015
Authors: Lori B Daniels; Gail A Laughlin; Donna Kritz-Silverstein; Paul Clopton; Wei-Chung Chen; Alan S Maisel; Elizabeth Barrett-Connor Journal: Am J Med Date: 2011-07 Impact factor: 4.965
Authors: Julie K Bower; Mariana Lazo; Kunihiro Matsushita; Jonathan Rubin; Ron C Hoogeveen; Christie M Ballantyne; Elizabeth Selvin Journal: Am J Hypertens Date: 2015-03-16 Impact factor: 2.689
Authors: Sahera Dirajlal-Fargo; Bruce Kinley; Ying Jiang; Chris T Longenecker; Corrilynn O Hileman; Sara Debanne; Grace A McComsey Journal: AIDS Date: 2015-01-28 Impact factor: 4.177
Authors: Francesco Ruggieri; Marco Gemma; Maria Rosa Calvi; Elisa Nicelli; Andrea Agarossi; Luigi Beretta Journal: Neurocrit Care Date: 2012-12 Impact factor: 3.210
Authors: Michael G Fradley; Martin G Larson; Susan Cheng; Elizabeth McCabe; Erin Coglianese; Ravi V Shah; Daniel Levy; Ramachandran S Vasan; Thomas J Wang Journal: Am J Cardiol Date: 2011-08-23 Impact factor: 2.778